Chr t(4;9;22)(q21;q34;q11)

Chemotherapy with weekly bortezomib, cyclophosphamide and dexamethasone was preferred considering the risk of drug interactions and pancytopenia when combined with nilotinib for CML. Due to the rarity of coexistence of two hematological malignancy in the same patient, we have scarce data on treatment approach. Our case demonstrates that nilotinib combined with certain myeloma therapy can be considered safe and efficient in a case of CML and MM comorbidity.